NCT06205732View on ClinicalTrials.gov

A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Carcinoma, Hepatocellular
Interventions
OTHER

Immunotherapy, targeted therapy.

Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).

Trial Locations (1)

250000

RECRUITING

the Qianfoshan Hospital, Jinan

All Listed Sponsors
lead

Qianfoshan Hospital

OTHER